Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Am J Hematol 2011 Jul 27;86(7):533-9. Epub 2011 Apr 27.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria.

The second generation BCR/ABL kinase inhibitor nilotinib is increasingly used for the treatment of imatinib-resistant chronic myeloid leukemia (CML). So far, nilotinib is considered a well-tolerated drug with little if any side effects, although an increase in the fasting glucose level has been reported. We examined a series of 24 consecutive CML patients treated with nilotinib in our center for the development of non-hematologic adverse events. Three of these 24 CML patients developed a rapidly progressive peripheral arterial occlusive disease (PAOD) during treatment with nilotinib. In all three cases, PAOD required repeated angioplasty and/or multiple surgeries within a few months. No PAOD was known before nilotinib-therapy in these patients, although all three had received imatinib. In two patients, pre-existing risk factors predisposing for PAOD were known, and one of them had developed diabetes mellitus during nilotinib. In the other 21 patients treated with nilotinib in our center, one less severe PAOD, one myocardial infarction, one spinal infarction, one subdural hematoma, and one sudden death of unknown etiology were recorded. In summary, treatment with nilotinib may be associated with an increased risk of vascular adverse events, including PAOD development. In a subgroup of patients, these events are severe or even life-threatening. Although the exact mechanisms remain unknown, we recommend screening for pre-existing PAOD and for vascular risk factors such as diabetes mellitus in all patients before starting nilotinib and in the follow up during nilotinib-therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.22037DOI Listing
July 2011
75 Reads

Publication Analysis

Top Keywords

nilotinib
9
nilotinib center
8
treatment nilotinib
8
treated nilotinib
8
patients treated
8
diabetes mellitus
8
risk factors
8
adverse events
8
cml patients
8
arterial occlusive
8
occlusive disease
8
progressive peripheral
8
peripheral arterial
8
paod
7
patients
7
pre-existing risk
4
developed rapidly
4
patients pre-existing
4
three received
4
received imatinib
4

References

(Supplied by CrossRef)
The biology of chronic myelogenous leukemia
Faderl et al.
N Eng J Med 1999
New tyrosine kinase inhibitors in chronic myeloid leukemia
Martinelli et al.
Haematologica 2005
Optimizing therapy of chronic myeloid leukemia
Deininger et al.
Exp Hematol 2007
Beyond dose escalation: Clinical options for relapse or resistance in chronic myelogenous leukemia
Cortes et al.
J Natl Compr Canc Netw 2008

Similar Publications